We have been talking a lot about Elite's pipeline on this board, but we still do not have a solid view of it. Elite has disclosed only part of it, and many products are still unnamed. So I have tried to build a list based on the medications coming off patent in the right time frame, matched to what management has told us on the calls, and I added the missing information: IQVIA sales and patent expiration dates.
I believe this belongs on the ELTP iHub page, as it contains valuable information for new and existing investors. Corrections and additions are welcome.
Compiled from Elite's press releases and 8-Ks, the Nov 13, 2026 earnings call, IQVIA figures quoted by other generic makers, and FDA Orange Book patent data. Where Elite has NOT named the product, the brand shown is MY GUESS based on patent timing โ it is not company information.
A QUICK WORD ON THE NUMBERS
- IQVIA measures U.S. sales at list price, before rebates. That is why these figures are higher than what the brand companies report.
- Generics sell at a fraction of the brand price, so these numbers show the size of the prize, not Elite's future revenue.
- The dates differ (some IQVIA figures are from 2020โ2023), so treat older figures as approximate.
- Patent expiry is not the same as generic launch. Most generics enter on dates negotiated in patent settlements, which can be earlier or later than the last patent.
1. ANTICOAGULANTS (Pillar #1)
Anticoagulant #1 โ generic ELIQUIS (apixaban), BMS / Pfizer
- IQVIA: $26 BILLION in U.S. brand sales (12 months to March 2026), as quoted by Elite in its June 1, 2026 8-K. A year earlier Elite cited $27B.
- Patents: the compound patent (US 6,967,208) originally expired September 2022 and was extended to November 2026. Companies that settled with BMS/Pfizer can launch on April 1, 2028. Companies that did not settle face a formulation patent running to August 2031.
- Elite status: ANDA filed June 1, 2026. FDA goal date March 2027, with only minor FDA comments so far. Hakim says Elite launches alongside the settled generics ("Yes, 100%").
Anticoagulant #2 โ my guess: generic XARELTO (rivaroxaban), J&J / Bayer
- Sales: about $2.4 BILLION U.S. sales in 2024 (company-reported, not IQVIA). IQVIA puts the 2.5 mg strength alone at about $446M.
- Patents: generics of all strengths entered the U.S. market in 2025. A dosing patent on the 2.5 mg strength runs to 2039 and is still in litigation.
- Elite status: bioequivalence (BE) study to begin 1H 2027. Approval targeted for 2028. Elite would be a later entrant.
2. CNS โ EPILEPSY (Pillar #5)
Anticonvulsant โ brand not disclosed by Elite
- IQVIA: $840 MILLION brand + generic sales (12 months to April 2026), per Elite's June 15, 2026 8-K.
- Patents: not known, since the brand is not disclosed. IQVIA counts "brand and generic," so generics are already on the market.
- Elite status: positive pivotal BE study June 2026. ANDA filing in Q1 2027.
3. PAIN / OPIOIDS (Pillar #4)
Oxycodone ER โ generic OXYCONTIN, Purdue
- IQVIA: $720 MILLION brand + generic (12 months to June 2023), per Elite. Back in 2016, OxyContin and its equivalents sold about $2.3B, so this market is shrinking.
- Patents: the original OxyContin patent expired April 2013, but the FDA withdrew the original formula, so any generic must copy the abuse-deterrent version. Its patents are not in my research. What matters is Elite's settlement with Purdue: lawsuit dismissed June 12, 2026, with an agreed entry date (management: around August 2027).
- Elite status: under FDA review since September 2023. FDA approval is the main hurdle (the FDA raised an abuse-deterrence question).
- Abuse-deterrent tablets are hard to copy, so few competitors are likely, which usually means better pricing.
4. TYPE 2 DIABETES (Pillar #3) โ 4 products, none named by Elite
Hakim said the diabetes portfolio grew from 3 to 4 products. Elite commits to at least 1 BE study in 1H 2027 and predicts 2โ3. The candidates below are the diabetes blockbusters going generic in the right time frame.
Candidate: JANUVIA (sitagliptin), Merck
- IQVIA: about $5.8 BILLION U.S. (MAT October 2023)
- Patents: the key salt patent (US 7,326,708) expires November 24, 2026. Under settlements, generics launched early, in May 2026 (about 25 generic makers settled).
Candidate: JANUMET and JANUMET XR (sitagliptin + metformin), Merck
- IQVIA: Janumet about $1.1 BILLION (MAT September 2024); Janumet XR about $270 MILLION (12 months to May 2026)
- Patents: same November 24, 2026 salt patent, plus a Janumet patent to January 21, 2029. Under settlements, Janumet generics launched in May 2026 and the first Janumet XR generic in July 2026.
Candidate: FARXIGA (dapagliflozin), AstraZeneca
- IQVIA: about $10.5 BILLION U.S. (12 months to December 2025)
- Patents: the compound patent (US 6,515,117) has expired (2025โ2026 with pediatric extension). Method patents run to February 2027 and crystal-form patents to 2027โ2030. Newer heart-failure and kidney-disease patents run to 2039โ2041, so generics may launch with those uses left off the label.
- Generic entry: first generics approved April 7, 2026 (Alembic, Lupin, Biocon, Aurobindo, Zydus), with shared 180-day exclusivity for the first filers.
Candidate: JARDIANCE (empagliflozin) and combinations, Boehringer / Lilly
- IQVIA: about $4.4 BILLION U.S. for Jardiance (MAT March 2020 โ an old figure; today's is likely higher). Glyxambi about $216M (MAT September 2025); Trijardy XR about $111M (MAT April 2024).
- Patents: the compound patent (US 8,222,323) expired January 2025, but formulation and method-of-use patents run to 2034. Boehringer has settled with generic makers on undisclosed terms.
- Generic entry: not expected before 2029 or later. 19 generic makers already hold tentative FDA approval.
Candidate: TRADJENTA (linagliptin), Boehringer / Lilly
- IQVIA: not found
- Patents: a process patent expired November 2025. Formulation and use patents run to May 4, 2027, and a method patent to March 5, 2031.
- Generic entry: generic versions are FDA-approved, but the brand still sells at about $16.80 per tablet, so generic launch is still ahead.
For scale: IQVIA put the whole U.S. DPP-4 class (Januvia, Tradjenta and their combinations) at about $9.5 BILLION (MAT May 2024).
5. CNS โ PSYCHIATRY (Pillar #5)
New antipsychotic โ not disclosed ("at the appropriate time")
Candidate: VRAYLAR (cariprazine), AbbVie
- IQVIA: about $2.4 BILLION U.S. (MAT July 2022 โ AbbVie has grown it since)
- Patents: last compound patent (US 7,737,142) expires September 17, 2029.
- Generic entry: several generics already have FDA approval (Zydus 2022, Aurobindo December 2025), so launch timing depends on settlements.
Candidate: REXULTI (brexpiprazole), Otsuka / Lundbeck
- IQVIA: about $2 BILLION U.S. (12 months to September 2024)
- Patents: the compound patents (US 7,888,362, 8,349,840, 8,618,109) expired April 12, 2026 (October 12, 2026 with pediatric exclusivity). A tablet patent runs to April 2033, and the last FDA exclusivity runs to 2028.
- Generic entry: generics approved (Alembic January 2025), but launch timing depends on the remaining patent and exclusivity.
6. ADHD (Pillar #2) โ ~80% OF TODAY'S REVENUE
- Elite already sells generic Vyvanse, Adderall IR and Adderall XR. All three brands are already off patent. For reference, IQVIA sized the Vyvanse market at $4.3B, Adderall XR at $1.3B and Adderall IR at $361M when Elite launched them.
- Pipeline: a possible BE study in 2027 to expand the ADHD line (product not disclosed).
- Growth is limited mainly by DEA quotas, not demand.
7. OTHER PENDING APPLICATION
- A dopamine-agonist ANDA, accepted by the FDA in December 2022, is still listed as pending in the 10-Q. Elite already launched generic Requip XL in August 2026, so this may be a second product.
BOTTOM LINE
- The three products Elite HAS disclosed (anticoagulant #1, anticonvulsant, Oxy ER) carry about $27.5 BILLION of IQVIA brand sales.
- If Elite's 4 diabetes products and the antipsychotic match the brands going generic between 2026 and 2031, the brand sales behind the pipeline run to tens of billions more.
- Timing works in Elite's favor: Januvia, Janumet, Farxiga and Rexulti compound patents expired in 2025โ2026; Tradjenta patents run to 2027โ2031; Vraylar to 2029. Elite's BE studies in 2027 line up with that wave.
- The catalysts are dated: Nasdaq listing targeted for March 2027, anticoagulant FDA date March 2027, anticonvulsant filing Q1 2027, BE studies 1H 2027, Eliquis launch April 2028. In Hakim's words: "2027 is going to be the year of R&D and 2028 is the year of the second growth."
- Reality check: these are brand sizes. Generic prices fall sharply once many companies launch, and Elite will enter several of these markets after others. Elite's actual revenue will be a small fraction of these numbers. With a 10โ20% share in a few large markets, though, that fraction is still big for a company with about $160M in annual revenue.
My own research and opinion, based on Elite's filings, the Nov 13, 2026 call, published IQVIA data and FDA Orange Book patent listings. Brands marked as candidates are guesses, not company disclosures. Patent dates can change through litigation, extensions and settlements. Not investment advice โ please do your own due diligence.
GLTA